![]() ![]() This practice is able to specifically target healthcare costs, as biosimilar products often come at a reduced pricetag, about 15% to 25% lower than the reference products. Biosimilar products can be used in patients who have been previously treated with the reference product, or those who have been newly prescribed the product. ![]() With this new approval, Semglee can be substituted out for Lantus by the pharmacy (otherwise known as "pharmacy-level substitution") without a prescriber intervening - similar to with generic drugs. Semglee "can be expected to produce the same clinical result as Lantus" in any given patient, according to the FDA, and potential safety risks or risk of diminished efficacy when switching between the two products is no greater than staying on Lantus. Evidence for Semglee's new interchangeable approval showed there to be no "clinically meaningful difference" between the biosimilar and reference product, in terms of safety, purity, and potency. This new approval deems Semglee as completely interchangeable with the reference product, Lantus, which was first approved in 2000. ![]() Semglee was first approved in June 2020 as a biosimilar to Lantus (insulin glargine) for adults and pediatric patients with type 1 diabetes and for adults with type 2 diabetes. ![]()
0 Comments
Leave a Reply. |